ARONJ A Guide to Research
AOCMF is excited to announce the release of its latest research publication: Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ)—a Guide to Research. The publication outlines the latest thinking and research on definitions and classifications of ARONJ, its clinical features, risk factors, treatment outcomes, and using small and large animal models to further explore and learn about the condition. For AOCMF members, this exciting document is now available.
An association between antiresorptive therapy and osteonecrosis of the jaws (ONJ) was first described in 2003. As we unravel the many biologic processes and risk factors associated with this condition, numerous terms have emerged to describe it, including bisphosphonate-induced ONJ (BIONJ), bisphosphonate-related ONJ (BRONJ), antiresorptive-induced ONJ (ARONJ), antiresorptive-associated ONJ (ARONJ), medication-related ONJ (MRONJ), and antiresorptive drug-related ONJ (ARONJ), which is now the primary term used in this book. ARONJ is a significant concern owing to its unknown pathophysiology, lack of established management regimens, and because of the millions of patients currently taking antiresorptive agents. While it has now been more than a decade since the first report of osteonecrosis associated with bisphosphonates, the pathophysiology has still not been determined. While the mission of this book is to provide contemporary evidence and insight into ARONJ, the ultimate goal is to provide the best care for our patients. The various terminologies used by the experts that author this book reflect the challenges we continue to face as researchers and clinicians in understanding the pathogenesis, risk factors, diagnosis, and management of this condition. We are fortunate to have internationally acclaimed authors involved in this project, and they are to be applauded for their time and effort in contributing to this book.